-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Maintains Buy on Starling Oncology, Raises Price Target to $9

Benzinga·10/14/2026 09:46:57
Listen to the news
Needham analyst Matthew Shea maintains Starling Oncology (NASDAQ:STLN) with a Buy and raises the price target from $7 to $9.